Understanding drug preferences, different perspectives-Reference-Cited by-同舟云学术

Understanding drug preferences, different perspectives

Published:2015-05-22 Issue:6 Volume:79 Page:978-987
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Mol Peter G. M.¹²,Arnardottir Arna H.¹,Straus Sabine M. J.²³,de Graeff Pieter A.¹²,Haaijer-Ruskamp Flora M.¹,Quik Elise H.⁴,Krabbe Paul F. M.⁴,Denig Petra¹

Affiliation:

1. Department of Clinical Pharmacy and Pharmacology; University of Groningen, University Medical Center Groningen; Groningen The Netherlands

2. Dutch Medicines Evaluation Board (CBG-MEB); Utrecht The Netherlands

3. Department of Medical Informatics; Erasmus Medical Center; Rotterdam The Netherlands

4. Department of Epidemiology; University of Groningen, University Medical Center Groningen; Groningen The Netherlands

Funder

Top Institute Pharma

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12566/fullpdf

Reference39 articles.

1. GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm;Gale;BMJ,2013

2. Rosiglitazone: a cautionary tale;Godlee;BMJ,2010

3. Rosiglitazone: what went wrong?;Cohen;BMJ,2010

4. New drugs and indications in 2010: inadequate assessment; patients at risk;Prescrire International;Rev Prescrire,2011

5. The risks of risk aversion in drug regulation;Eichler;Nat Rev Drug Discov,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment;Journal of Managed Care & Specialty Pharmacy;2023-02

2. Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists;Patient Preference and Adherence;2022-12

3. Patients’ Preference Between DPP4i and SGLT2i for Type 2 Diabetes Treatment: A Cross-Sectional Evaluation;Patient Preference and Adherence;2022-05

4. Alignment between outcomes and minimal clinically important differences in the Dutch type 2 diabetes mellitus guideline and healthcare professionals’ preferences;Pharmacology Research & Perspectives;2021-05

5. Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study;Frontiers in Pharmacology;2021-02-25